Table 1. Clinicopathological features according to MAPT-AS1 alterations in BC patients.
| Clinicopathological features | n | MAPT-AS1 | χ2 | P | |
|---|---|---|---|---|---|
| Low expression | High expression | ||||
| Age, n (%) | 1.818 | 0.370 | |||
| ≤52 years | 9 | 6 (66.7) | 3 (33.3) | ||
| >52 years | 11 | 4 (36.4) | 7 (63.6) | ||
| Size, n (%) | 9.899 | 0.005** | |||
| ≤3 cm | 11 | 9 (81.8) | 2 (18.2) | ||
| >3 cm | 9 | 1 (11.1) | 8 (88.9) | ||
| Tumor grade, n (%) | 7.200 | 0.023* | |||
| I and II | 10 | 7 (70.0) | 3 (30.0) | ||
| III | 10 | 1 (10.0) | 9 (90.0) | ||
| Lymphatic metastasis, n (%) | 1.818 | 0.370 | |||
| Yes | 9 | 6 (66.7) | 3 (33.3) | ||
| No | 11 | 4 (36.4) | 7 (63.6) | ||
| Estrogen receptor, n (%) | 0.220 | 1.000 | |||
| Negative | 7 | 4 (57.1) | 3 (42.9) | ||
| Positive | 13 | 6 (46.2) | 7 (53.8) | ||
| Progesterone receptor, n (%) | 0.220 | 1.000 | |||
| Negative | 7 | 4 (57.1) | 3 (42.9) | ||
| Positive | 13 | 6 (46.2) | 7 (53.8) | ||
| HER2, n (%) | 0.800 | 0.656 | |||
| Negative | 10 | 6 (60.0) | 4 (40.0) | ||
| Positive | 10 | 4 (40.0) | 6 (60.0) | ||
| Ki-67, n (%) | 1.250 | 0.582 | |||
| ≤14 | 4 | 3 (75.0) | 1 (25.0) | ||
| >14 | 16 | 7 (43.8) | 9 (56.2) | ||
*, P <0.05; **, P<0.01. BC, breast cancer; HER2, human epidermal growth factor receptor 2.